HIV progression to AIDS: Bioinformatics approach to determining the mechanism of action

Current HIV Research

Volumn 11, Issue 1, 2013, Pages 30-42

  Nwankwo, Norbert ^a   Seker, Huseyin ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

CD4; Gp120; Macrophage loving viruses; Resonant recognition model; T cell lymphocyte loving viruses

Indexed keywords

GLYCOPROTEIN GP 120;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ARTICLE; BINDING AFFINITY; BIOINFORMATICS; CD4+ T LYMPHOCYTE; CERCOPITHECUS; COMPUTER MODEL; DISEASE COURSE; FOURIER TRANSFORMATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NUCLEOTIDE SEQUENCE; PATHOGENESIS; RESONANT RECOGNITION MODEL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL TROPISM;

EID: 84876713873     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016213804999221     Document Type: Article

References (70)

1. Smith PL, Dalgleish A. Subtle Mimicry of HLA by HIV-1 gp120 a role for anti HLA antibodies? Open Autoimmun J 2010; 2: 104-116.
2. Bandera A, Ferrario G, Saresella M, et al. CD4+ T cell depletion, immune activation and increased production of regulatory T cells in the thymus of HIV-infected individuals. PLoS One 2010; 5(5): e10788-e10795.
3. Corbeil J, Richman DD. Productive infection and subsequent interaction of CD4-gp120 at the cellular membrane is required for HIV-induced apoptosis of CD4+ T cells. J Gen Virol 1995; 76: 681-690.
4. Lernmark A. Autoimmune diseases: are markers ready for prediction? J Clin Invest 2001; 108(8): 1091-1096.
5. Karlsson A, Parsmyr K, Sandstrm E, et al. MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994; 32(2): 364-370.
6. Langford SE, Ananworanich J, Cooper DA. Predictors of disease progression in HIV infection: A review. AIDS Res Ther 2007; 4: 1-11.
7. Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328(5): 327-335.
8. Cheingsong-Popov R, Weis RA, Nagy K, Clapham P. Human TCell leukaemia virus type I: Induction of syncytia and inhibition by patients' sera. Int J Cancer 1983; 32(3): 321-328.
9. Collman R, Balliet JW, Gregory SA, et al. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1. J Virol 1992; 66(12): 7517-7521.
10. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85: 1149-1158.
11. Ribeiro RM, Hazenberg MD, Perelson AS, Davenport MP. Naïve and memory cell turnover as drivers of CCR5-to-CXCR4 tropism switch in human immunodeficiency virus type 1: implications for therapy. J Virol 2006; 80: 802-809.
12. Lusso P. HIV and the chemokine system: 10 Years Later. EMBO J 2006; 25: 447-456.
13. Polzer S, Dittmar MT, Schmitz H, Schreiber M. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002; 304: 70-80.
14. Callaway DS, Ribeiro MR, Nowak MA. Virus phenotype switching and disease progression in HIV-1 infection. Royal Society B: Proc Biol Sci 1999; 266: 2523-3530.
15. Chen JJ, Cloyd MW. The potential importance of HIV-induction of lymphocyte homing to lymph nodes. Int Immunol 1999; 11(10): 1591-1594.
16. Blaak H, Vant-Wout AB, Brouwer M, Hooibrink B, Hovenkamp E, Schuitemaker H. In vivo HIV-1 infection of CD45RA(+)CD4(+) T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4(+) T cell decline. Proc Natl Acad Sci USA 2000; 97(3): 1269-1274.
17. Larosa GJ, Davide JP, Weinhold K, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249: 932-935.
18. Dejucq N, Simmons G, Clapham RP. T-cell line adaptation of human immunodeficiency virus type 1 strain SF162: effects on envelope, vpu and macrophage-tropism. J Gen Virol 2000; 81: 2899-2904.
19. Regoes RR, Bonheoffer S. The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 2005; 13: 269-277.
20. Cosic I. Macromolecular bioactivity: is it resonant interaction between macromolecules?--Theory and applications. IEEE Trans Biomed Eng 1994; 41(12): 1101-1114.
21. Cosic I. Analysis of HIV proteins using DSP techniques. IEEE Engineering in Medicine and Biology Society: Proceeding of IEEE Annual International Conference 2001; 2001(3): 2886-2889; 2001.
22. Pirogova E, Akay M, Cosic I. Investigating the interaction between oncogene and tumor suppressor protein. IEEE Trans Inf Technol Biomed 2009; 13(1): 10-15.
23. de Trad CH, Fang Q, Cosic I. Protein sequence comparison based on the wavelet transform approach. Protein Eng 2002; 15(3): 193-203.
24. Pirogova E, Cosic I. Application of signal processing in computational analysis of HSPS interactions. Biomedical Engineering: Proceedings of the 2nd IASTED Intl Conf., Innsbruck, Austria, 16-18 February 2004; 2004: 345-351; 2004.
25. Vaidyanathan PP. Genomics and proteomics: A signal processors tour. IEEE Circuits and Systems Magazine 2004; 4(4): 6-29.
26. Cochrane JH. Time series for macroeconomics and finance. Spring 1997.
27. Smith SW. The scientist and engineer's guide to digital signal processing. California Technical Publishing 2002.
28. Jain E, Bairoch A, Duvaud S, et al. Infrastructure for the life sciences: design and implementation of the UniProt website. BMC Bioinformatics 2009; 10: 136.
29. Endres MJ, Clapham PR, Marsh M, et al. CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 1996; 87: 745-756.
30. Jeffs SA, Shotton C, Balfe P, McKeating JA. Truncated gp120 envelope glycoprotein of human immunodeficiency virus 1 elicits a broadly reactive neutralizing immune response. J Gen Virol 2002; 83(Pt 11): 2723-2732.
31. Tokunaga K, Michael L, Greenberg ML, et al. Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates. J Virol 2001; 75(15): 6776-6785.
32. Simon F, Mauclre P, Roques P, et al. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O. Nat Med 1998; 4(9): 1032-1037.
33. Chowdhury HI, Bentsman G, Choe W, Potash JM, Volsky JD. The macrophage response to HIV-1: Intracellular control of X4 virus replication accompanied by activation of chemokine and cytokine synthesis. J Neurovirol 2002; 8: 599-610.
34. Brandful JA, Coetzer ME, Cilliers T, et al. Phenotypic characterization of HIV type 1 isolates from Ghana. AIDS Res Hum Retroviruses 2007; 23(1): 144-152.
35. Fauci AS. Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 1993; 262: 1011-1018.
36. Chu C, Selwyn PA. Diagnosis and initial management of acute HIV infection. Am Fam Physician 2010; 81(10): 1239-1244.
37. Oxenius A, Price DA, Easterbrook PJ, et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci USA 2000; 97(7): 3382-3387.
38. Koopman JS, Jacquez JA, Welch GW, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14(3): 249-258.
39. Kinter A, Catanzaro A, Monaco J, et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc Natl Acad Sci USA 1998; 95: 11880-11885.
40. Hirsch I, de Mareuil J, Salaun D, Chermann JC. Genetic control of infection of primary macrophages with T-cell-tropic strains of HIV-1. Virology 1996; 219: 257-261.
41. Pollakis G, Abebe A, Kliphuis A, et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol 2004; 78(6): 2841-2852.
42. Miller ED, Duus KM, Townsend M, et al. Human immunodeficiency virus type 1 IIIB selected for replication in vivo exhibits increased envelope glycoproteins in virions without alteration in coreceptor usage: separation of in vivo replication from macrophage tropism. J Virol 2001; 75(18): 8498-8506.
43. Sakaida H, Hori T, Yonezawa A, et al. T-tropic human immunodeficiency virus type 1 (HIV-1)-derived V3 loop peptides directly bind to CXCR-4 and inhibit T-tropic HIV-1 infection. J Virol 1998; 72(12): 9763-9770.
44. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD. In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 1997; 71(3): 2059-2071.
45. Chehimi J, Prakash K, Shanmugam V, et al. CD4-independent infection of human peripheral blood dendritic cells with isolates of human immunodeficiency virus type 1. J Gen Virol 1993; 74: 1277-1285.
46. Stevenson M, Haggerty S, Lamonica C, Mann AM, Meier C, Wasiak A. Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis. J Virol 1990; 64(8): 3792-3803.
47. Ivey-Hoyle M, Culp JS, Chaikin MA, et al. Envelope glycoproteins from biologically diverse isolates of immunodeficiency viruses have widely different affinities for CD4. Proc Natl Acad Sci USA 1991; 88: 512-516.
48. Myers G, Korber B, Wain-Hobson S, Jeang K-T, Henderson L, EPavlakis GN. Human retroviruses and AIDS 1992: A compilation and analysis of nucleic acid and amino acid sequences. Theoretical biology and biophysics group, Los Alamos National Laboratory, Los Alamos, NM 1992.
49. Gurgo C, Guo HG, Franchini G, et al. Envelope sequences of two new United States HIV-1 isolates. Virology 1988; 164(2): 531-536.
50. CDC agent summary statement. Human T-lymphotropic virus type III/lymphadenopathy-associated virus: agent summary statement. MMWR Morb Mortal Wkly Rep 1986; 35(34): 540-542+547-549.
51. Getchell JP, Heath JL, Hicks DR, Sporborg C, Mcgrath CR, Kalyanaraman VS. Continuous production of a cytopathic human T-lymphotropic virus in a permissive neoplastic T-cell line. J Clin Microbiol 1986; 23(4): 737-742.
52. Tanese N, Sodroski J, Haseltine WA, Go SP. Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli. J Virol 1984; 59(3): 743-745.
53. Blumberg BM, Epstein LG, Saito Y, Chen D, Sharer LR, and Anand R. Human immunodeficiency virus type 1 nef quasispecies in pathological tissue. J Virol 1992; 66(9): 5256-5264.
54. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR-5 usage. Virology 1998; 240: 83-92.
55. Schols D, Struyf S, Van Damme J, Est JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997; 186(8): 1383-1388.
56. Takeuchi Y, Hoshino H, Miura T, Hayami M, Clapham P. R, Weiss RA. Preferential susceptibilities of adherent-cells derived from human rrains to an HIV-1 mutant and HIV-2 and SIV isolates. International AIDS Society: Proceedings of the 7th Int Conf AIDS 1991; 7: 100 (abstract no. M.A.1035).
57. Lazdins JK, Klimkait T, Woods-Cook K, et al. The replicative restriction of lymphocytotropic isolates of HIV-1 in macrophages is overcome by TGF-beta. AIDS Res Hum Retroviruses 1992; 8(4): 505-511.
58. Gao F, Robertson DL, Carruthers CD, et al. A comprehensive panel of near-full-length clones and reference sequences for nonsubtype B isolates of human immunodeficiency virus type 1. J Virol 1998; 72(7): 5680-5698.
59. Torre VS, Marozsan AJ, Albright JL, et al. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J Virol 2000; 74(10): 4868-4876.
60. Huet T, Kerbarh O, Schols D, et al. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2010; 54(1): 134-142.
61. Dorr P, Westby M, Dobbs S, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49(11): 4721-4732.
62. Huet T, Dazza MC, Brun-Vzinet F, Roelants GE, Wain-Hobson S. A highly defective HIV-1 strain isolated from a healthy Gabonese individual presenting an atypical western blot. AIDS 1989; 3(11): 707-715.
63. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201(9): 1407-1419.
64. Barnett SW, Quiroga M, Werner A, Dina D, Levy JA. Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J Virol 1993; 67(2): 1006-1014.
65. Grez M, Dietrich U, Balfe P, et al. Genetic analysis of human immunodeficiency virus type 1 and 2 (HIV-1 and HIV-2) mixed infections in India reveals a recent spread of HIV-1 and HIV-2 from a single ancestor for each of these viruses. J Virol 1994; 68(4): 2161-2168.
66. Mosier E. Distinct rate and patterns of human CD4+ T-cell depletion in hu-PBL-SCID mice infected with different isolates of the human immunodeficiency virus. J Clin Immunol 1995; 15(6): 130-133.
67. Hirsch V, Riedel N, Kornfeld H, Kanki PJ, Essex M, Mullins JI. Cross-reactivity to human T-lymphotropic virus type III/lymphadenopathy-associated virus and molecular cloning of simian T-cell lymphotropic virus type III from African green monkeys. Proc Natl Acad Sci USA 1986; 83: 9754-9758.
68. Puffer B A, Ohlmann S, Edinger A L, et al. CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 2002; 76(6): 2595-2605.
69. Takehisa J, Kraus MH, Decker JM, et al. Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees. J Virol 2007; 81(14): 7463-7475.
70. Lathey JL, Brambilla D, Goodenow MM, et al. Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient? J Leukoc Biol 2000; 68: 324-330.